Copyright Reports & Markets. All rights reserved.

(Post-pandemic Era)-Global Biosimilars/follow-on-biologics Market Segment Research Report 2022

Buy now

Table of Contents

    Global Biosimilars/follow-on-biologics Market Segment Research Report 2022

      1. Research Scope

        2. Market Overview

        • 2.1 Product Introduction, Application, Picture
        • 2.2 Global Biosimilars/follow-on-biologics Market by Value
          • 2.2.1 Global Biosimilars/follow-on-biologics Revenue by Type
          • 2.2.2 Global Biosimilars/follow-on-biologics Market by Value (%)
        • 2.3 Global Biosimilars/follow-on-biologics Market by Production
          • 2.3.1 Global Biosimilars/follow-on-biologics Production by Type
          • 2.3.2 Global Biosimilars/follow-on-biologics Market by Production (%)

        3. The Major Driver of Biosimilars/follow-on-biologics Industry

        • 3.1 Historical & Forecast Global Biosimilars/follow-on-biologics Demand
        • 3.2 Largest Application for Biosimilars/follow-on-biologics (2018-2028)
        • 3.3 The Major Downstream Company in China Market 2022

        4. Global and Regional Biosimilars/follow-on-biologics Market

        • 4.1 Regional Market Size in Terms of Production & Demand (2022)
        • 4.2 Regional Market Share in Terms of Revenue (2018-2022)
        • 4.3 Concentration Ratio (CR5& CR10) of Biosimilars/follow-on-biologics Market
        • 4.4 Mergers & Acquisitions, Expansion Plans

        5. US Biosimilars/follow-on-biologics Production, Demand (2018-2028)

        • 5.1 Current and Estimated Production Breakdown by Type
        • 5.2 Current and Estimated Demand Breakdown by Type
        • 5.3 Current and Estimated Demand Breakdown by Application
        • 5.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 5.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        6. Europe Biosimilars/follow-on-biologics Production, Demand (2018-2028)

        • 6.1 Current and Estimated Production Breakdown by Type
        • 6.2 Current and Estimated Demand Breakdown by Type
        • 6.3 Current and Estimated Demand Breakdown by Application
        • 6.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 6.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        7. China Biosimilars/follow-on-biologics Production, Demand (2018-2028)

        • 7.1 Current and Estimated Production Breakdown by Type
        • 7.2 Current and Estimated Demand Breakdown by Type
        • 7.3 Current and Estimated Demand Breakdown by Application
        • 7.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 7.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        8. Japan Biosimilars/follow-on-biologics Production, Demand (2018-2028)

        • 8.1 Current and Estimated Production Breakdown by Type
        • 8.2 Current and Estimated Demand Breakdown by Type
        • 8.3 Current and Estimated Demand Breakdown by Application
        • 8.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 8.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        9. India Biosimilars/follow-on-biologics Production, Demand (2018-2028)

        • 9.1 Current and Estimated Production Breakdown by Type
        • 9.2 Current and Estimated Demand Breakdown by Type
        • 9.3 Current and Estimated Demand Breakdown by Application
        • 9.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 9.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        10. Korea Biosimilars/follow-on-biologics Production, Demand (2018-2028)

        • 10.1 Current and Estimated Production Breakdown by Type
        • 10.2 Current and Estimated Demand Breakdown by Type
        • 10.3 Current and Estimated Demand Breakdown by Application
        • 10.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 10.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        11. Southeast Asia Biosimilars/follow-on-biologics Production, Demand (2018-2028)

        • 11.1 Current and Estimated Production Breakdown by Type
        • 11.2 Current and Estimated Demand Breakdown by Type
        • 11.3 Current and Estimated Demand Breakdown by Application
        • 11.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 11.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        12. Global Biosimilars/follow-on-biologics Average Price Trend

        • 12.1 Market Price for Each Type of Biosimilars/follow-on-biologics in US (2018-2022)
        • 12.2 Market Price for Each Type of Biosimilars/follow-on-biologics in Europe (2018-2022)
        • 12.3 Market Price for Each Type of Biosimilars/follow-on-biologics in China (2018-2022)
        • 12.4 Market Price for Each Type of Biosimilars/follow-on-biologics in Japan (2018-2022)
        • 12.5 Market Price for Each Type of Biosimilars/follow-on-biologics in India (2018-2022)
        • 12.6 Market Price for Each Type of Biosimilars/follow-on-biologics in Korea (2018-2022)
        • 12.7 Market Price for Each Type of Biosimilars/follow-on-biologics in Southeast Asia (2018-2022)

        13. Industrial Chain (Impact of COVID-19)

        • 13.1 Biosimilars/follow-on-biologics Industrial Chain Analysis
        • 13.2 Downstream
        • 13.3 Impact of COVID-19
        • 13.4 Post-pandemic Era
        • 13.5 Technology Trends of Biosimilars/follow-on-biologics

        14. Biosimilars/follow-on-biologics Competitive Landscape

        • 14.1 Novartis (Sandoz)
          • 14.1.1 Novartis (Sandoz) Company Profiles
          • 14.1.2 Novartis (Sandoz) Product Introduction
          • 14.1.3 Novartis (Sandoz) Biosimilars/follow-on-biologics Sales, Revenue (2018-2022)
          • 14.1.4 Strategic initiatives
        • 14.2 Synthon Pharmaceuticals
          • 14.2.1 Synthon Pharmaceuticals Company Profiles
          • 14.2.2 Synthon Pharmaceuticals Product Introduction
          • 14.2.3 Synthon Pharmaceuticals Biosimilars/follow-on-biologics Sales, Revenue (2018-2022)
          • 14.2.4 Strategic initiatives
        • 14.3 Teva Pharmaceutical Industries
          • 14.3.1 Teva Pharmaceutical Industries Company Profiles
          • 14.3.2 Teva Pharmaceutical Industries Product Introduction
          • 14.3.3 Teva Pharmaceutical Industries Biosimilars/follow-on-biologics Sales, Revenue (2018-2022)
          • 14.3.4 Strategic initiatives
        • 14.4 LG Life Sciences
          • 14.4.1 LG Life Sciences Company Profiles
          • 14.4.2 LG Life Sciences Product Introduction
          • 14.4.3 LG Life Sciences Biosimilars/follow-on-biologics Sales, Revenue (2018-2022)
          • 14.4.4 Strategic initiatives
        • 14.5 Celltrion Biocon
          • 14.5.1 Celltrion Biocon Company Profiles
          • 14.5.2 Celltrion Biocon Product Introduction
          • 14.5.3 Celltrion Biocon Biosimilars/follow-on-biologics Sales, Revenue (2018-2022)
          • 14.5.4 Strategic initiatives
        • 14.6 Hospira
          • 14.6.1 Hospira Company Profiles
          • 14.6.2 Hospira Product Introduction
          • 14.6.3 Hospira Biosimilars/follow-on-biologics Sales, Revenue (2018-2022)
          • 14.6.4 Strategic initiatives
        • 14.7 Merck Serono (Merck)
          • 14.7.1 Merck Serono (Merck) Company Profiles
          • 14.7.2 Merck Serono (Merck) Product Introduction
          • 14.7.3 Merck Serono (Merck) Biosimilars/follow-on-biologics Sales, Revenue (2018-2022)
          • 14.7.4 Strategic initiatives
        • 14.8 Biogen idec
          • 14.8.1 Biogen idec Company Profiles
          • 14.8.2 Biogen idec Product Introduction
          • 14.8.3 Biogen idec Biosimilars/follow-on-biologics Sales, Revenue (2018-2022)
          • 14.8.4 Strategic initiatives
        • 14.9 Genentech (Roche)
          • 14.9.1 Genentech (Roche) Company Profiles
          • 14.9.2 Genentech (Roche) Product Introduction
          • 14.9.3 Genentech (Roche) Biosimilars/follow-on-biologics Sales, Revenue (2018-2022)
          • 14.9.4 Strategic initiatives

        15. Conclusion

          16. Methodology and Data Source

          Summary

          The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.

          2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.

          According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.

          Beijing Yanjing Bizhi Information Consulting Co., Ltd. (XYZResearch)released the 《(Post-pandemic Era)-Global Biosimilars/follow-on-biologics Market Segment Research Report 2022》, which aims to sort out the development status and trends of the Biosimilars/follow-on-biologics industry at home and abroad, estimate the overall market scale of the Biosimilars/follow-on-biologics industry and the market share of major countries, Biosimilars/follow-on-biologics industry, and study and judge the downstream market demand of Biosimilars/follow-on-biologics through systematic research, Analyze the competition pattern of Biosimilars/follow-on-biologics, so as to help solve the pain points of various stakeholders in Biosimilars/follow-on-biologics industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.

          Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Biosimilars/follow-on-biologics Market by XYZResearch Include
          USA
          Europe
          China
          Japan
          India
          Korea
          Southeast Asia
          Competitive Analysis; Who are the Major Players in Biosimilars/follow-on-biologics Market?
          Novartis (Sandoz)
          Synthon Pharmaceuticals
          Teva Pharmaceutical Industries
          LG Life Sciences
          Celltrion Biocon
          Hospira
          Merck Serono (Merck)
          Biogen idec
          Genentech (Roche)
          Major Type of Biosimilars/follow-on-biologics Covered in XYZResearch report:
          Human growth hormone
          Erythropoietin
          Monoclonal antibodies
          Insulin
          Interferon
          Granulocyte-Colony Stimulating Factor
          Others
          Application Segments Covered in XYZResearch Market
          Blood Disorders
          Oncology Diseases
          Chronic and Autoimmune Diseases
          Growth Hormone Deficiencies
          Others

          For any other requirements, please feel free to contact us and we will provide you customized report.

          Buy now